Castle Biosciences, Inc. (CSTL) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

via question and answer session. I would like to turn the call over to Camilla Zuccaro, Vice President of Investor Relations and Corporate Affairs. Please go ahead. Thank you, operator. Good afternoon, everyone. Welcome to Castle Bioscience's first quarter 2025 results conference call. Joining me today are CASEL's founder, president, and chief executive officer, Derek Massold, chief financial officer, Frank Stokes, and senior vice president, medical, Dr. Matthew Goldberg, board certified dermatologist and dermatopathologist. Information recorded on this call speaks only as of today, May 5th, 2025. Therefore, if you are listening to the replay or reading this transcript of this call, any time-sensitive information may no longer be accurate. A recording of today's call will be available on the Investor Relations page of the company's website for approximately three weeks following the conclusion of the call. Before we begin, I would like to remind you that some of the statements made today will contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our financial outlook, TAM, intended use populations, and similar items referenced in our earnings release issues today, and statements containing projections regarding future events or our future financial or operational results and performance. including our anticipated 2025 total revenue, our expectations regarding reimbursement for our products, opportunities for growth, impacts of seasonality and other trends, the size and structure of our commercial team, the timing of targeting milestones, and the impact of our investment and growth initiatives, including our ability to achieve lon...